Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system
This study summarized significant pulmonary adverse event signals associated with monoclonal antibodies approved for myeloma, emphasizing the significance of monitoring interstitial lung disease, respiratory failure, and infective pneumonia.
Authors
- Ting Liang (ORCID: https://orcid.org/0000-0002-7924-5195)
- Cong Xu (ORCID: https://orcid.org/0000-0003-3310-815X)
- Dongzheng Gai
- Junfeng Li (ORCID: https://orcid.org/0000-0001-9876-695X)
- Limei Yan
Institutions
- Sun Yat-sen University (CN)
- Changzhi Medical College (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1080/14740338.2025.2499218
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00